When one and one make three: HLA and EBV infection in MS

Neurology

Volumn 70, Issue 13 PART 2, 2008, Pages 1067-1068

  Marrie, Ruth Ann ^a,b  

^a HEALTH SCIENCES CENTRE   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; EPSTEIN BARR VIRUS ANTIGEN;

ANTIBODY RESPONSE; ANTIBODY TITER; BLOOD SAMPLING; DOSE RESPONSE; EDITORIAL; ENVIRONMENTAL FACTOR; EPSTEIN BARR VIRUS; GENETIC RISK; GENOTYPE; HAPLOTYPE; HLA SYSTEM; HUMAN LEUKOCYTE ANTIGEN DR15; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RISK FACTOR; SEROPREVALENCE; VIRUS INFECTION;

EID: 41549118482     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000307665.91437.cf     Document Type: Editorial

References (8)

1. Compston A, Coles A. Multiple sclerosis. Lancet 2002;359:1221-1231.
2. Coraddu F, Sawcer S, Feakes R, et al. HLA typing in the United Kingdom multiple sclerosis genome screen. Neurogenetics 1998;2:24-33.
3. Ascherio A, Munch M. Epstein-Barr virus and multiple sclerosis. Epidemiology 2000;11:220-224.
4. Alotaibi S, Kennedy J, Tellier R, Stephens D, Banwell B. Epstein-Barr virus in pediatric multiple sclerosis. JAMA 2004;291:1875-1879.
5. Visscher BR, Sullivan CB, Detels R, et al. Measles antibody titers in multiple sclerosis patients and HLA-matched and unmatched siblings. Neurology 1981;31:1142-1145.
6. Shirodaria PV, Haire M, Fleming E, Merrett JD, Hawkins SA, Roberts SD. Viral antibody titers. Comparison in patients with multiple sclerosis and rheumatoid arthritis. Arch Neurol 1987;44:1237-1241.
7. De Jager PL, Simon KC, Munger KL, Rioux JD, Hafler DA, Ascherio A. Integrating risk factors: HLADRB1* 1501 and Epstein-Barr virus in multiple sclerosis. Neurology 2008;70:1113-1118.
8. Delorenze GN, Munger KL, Lennette ET, Orentreich N, Vogelman JH, Ascherio A. Epstein-Barr virus and multiple sclerosis: evidence of association from a prospective study with long-term follow-up. Arch Neurol 2006;63:839-844.